Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that all-too-familiar routine of meetings, deadlines, and what-not has predictably returned. Getting started may be still more difficult today, thanks to a dollop of snow drops, which are blanketing the Pharmalot campus. Just when you thought spring had finally sprung, yes? Well, this calls for a few cups of stimulation as we juggle our laptop and our shovel. Meanwhile, here are some tidbits. Have a terrific day and do keep in touch …
Takeda Pharmaceutical (TKPYY) is facing questions over its ability to finance a debt-fueled deal for Shire (SHPG) without placing further strain on its stretched finances, The Telegraph tells us. Moody’s Investor Service has warned that Takeda will need to pile more debt onto its already weakened balance sheet if it wants to buy the drug maker. Shire has expanded through a series of acquisitions that have seen its annual revenues rise to more than $15 billion, but have also left it shouldering a $27 billion debt load.
May I observe that the continued snowy weather conditions in the Northeast US are becoming tiresome, although the observation itself is indeed becoming “tiresome.” (With no reference to shoveling activities … exercise is good for one, is it not?)
Comments are closed.